- Lilly slips on outlook
- Lilly investing in future, staying out of biotech 'bubble'
- 3Q EARNINGS: Lilly looks to future as revenue falls
- Alkermes claims ALKS 8700 success; third pipeline win in 2015
- INTERVIEW: Actavis CEO Saunders staying put as Allergan deal nears close
- Profile: Eurofarma's Martha Novelli Penna On Innovation And Acting